Cariprazine (Vraylar)
نویسندگان
چکیده

 CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well patient clinician perspectives, a drug or class.
 The inform non-binding recommendations that help guide decisions Canada's federal, provincial, territorial governments, with exception Quebec.
 This review assesses Cariprazine (Vraylar) 5 mg, 3 4.5 6 mg oral capsules.
 Indication: For treatment schizophrenia in adults.
منابع مشابه
Cariprazine in bipolar disorders.
Key Study Findings The authors report a multicenter (N = 497), randomized, double-blind, placebo-controlled study (NCT01058668). Patients were randomly assigned to placebo, cariprazine 3–6 mg/d, or cariprazine 6–12 mg/d for 3 weeks. The primary outcome was change from baseline to week 3 utilizing the Young Mania Rating Scale (YMRS). Both cariprazine groups were statistically significantly super...
متن کاملMechanism of action of cariprazine.
Cariprazine is a new therapeutic agent recently approved for the treatment of both schizophrenia and manic or mixed episodes associated with bipolar disorder, and is under investigation for the treatment of both bipolar depression and major depressive disorder.
متن کاملCariprazine for Schizophrenia and Bipolar Disorder.
Schizophrenia and bipolar disorder are associated with significant morbidity and mortality. Although atypical antipsychotics reduce positive and negative symptoms of schizophrenia as well as manic or mixed episodes of bipolar disorder, they are associated with varying degrees of metabolic adverse effects. This necessitates continued development of efficacious yet metabolically favorable treatme...
متن کاملCariprazine vs Risperidone for Negative Symptoms
Methods: Study subjects had a diagnosis of schizophrenia (DSM-IV-TR) with a duration of ≥2 years and had been clinically stable for ≥6 months but continued to have a Positive and Negative Syndrome Scale (PANSS) negative symptom score of ≥24 plus a score of ≥4 on at least 2 of the 4 core negative PANSS symptoms: blunted affect, passive social withdrawal, lack of spontaneity, and flow of conversa...
متن کاملUpdate on schizophrenia and bipolar disorder: focus on cariprazine
Schizophrenia and bipolar disorder are severe psychiatric disorders that are frequently associated with persistent symptoms and significant dysfunction. While there are a multitude of psychopharmacologic agents are available for treatment of these illnesses, suboptimal response and significant adverse consequences limit their utility. Cariprazine is a new, novel antipsychotic medication with do...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Canadian journal of health technologies
سال: 2022
ISSN: ['2563-6596']
DOI: https://doi.org/10.51731/cjht.2022.466